Minzasolmin

DB18961InvestigationalSmall molecule

Minzasolmin is under investigation in clinical trial NCT05543252 (An Extension Study to Evaluate the Long-term Efficacy, Safety and Tolerability of Minzasolmin (UCB0599) in Study Participants With Parkinson's Disease).

Mechanism: Pharmacologically active on Alpha-synuclein
Curator reviewed
Formula / weight: C₂₃H₃₁N₅OS · 425.6 g/mol (avg)
Code names: UCB-0599

Resolves to

Compound

UNII3N0435TG2DCAS1802518-92-8

Structure

InChIKeyGDFWCSZNQVAQGR-GOSISDBHSA-NSMILESCCCC[C@H](CC1=CNC2=CC=CC=C12)NC(=O)C1=CN=C(S1)N1CCN(C)CC1

Targets

P37840SNCA

What you can answer from here — as of July 09, 2026

1Protein targetEach mapped to UniProt, with action and pharmacological action

Listed above

5Clinical trialsPhase, status and sponsor resolved per trial

1+ReferenceStructured and connected to the statements they support

Which drugs share a target with Minzasolmin, and which of those have an active Phase 3 trial?

Answer this in Biopharma OS Sign in to your account

Create a free account or log in to explore the full data card.

Create Account